Raseglurant Explained

Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu₅ receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.^{[1] [2] [3]} It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.^{[4] [5]}

See also

• Basimglurant
• Dipraglurant
• Fenobam
• Mavoglurant

External links

• Development of ADX10059 Ended for Long-term Use - Addex Therapeutics

Notes and References

1. Book: Célanire S, Duvey G, Poli S, Rocher JP . mGluR2 activators and mGluR5 blockers advancing in the clinic for major CNS disorders. . Annual Reports in Medicinal Chemistry . January 2012 . 47 . 71–88 . Academic Press . https://books.google.com/books?id=y7GH165YoOsC&pg=PA80 . 978-0-12-397214-9.
2. Web site: Don't Dodge the Dentist – Tips for Dealing with Dental Anxiety. en-US. 2017-04-05.
3. Book: Stein MB, Steckler T . Behavioral Neurobiology of Anxiety and Its Treatment. 30 July 2010. Springer Science & Business Media. 978-3-642-02912-7. 397–.
4. Book: Dominguez C . Neurodegenerative Diseases. 18 November 2010. Springer Science & Business Media. 978-3-642-16758-4. 120–.
5. Book: Shaheen NJ . Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics. 25 March 2013. Elsevier Health Sciences. 978-1-4557-7175-2. 119–.